QSC ships research-grade cagrilintide (AM833) to New Zealand. Cagrilintide is a long-acting AMY1R agonist (amylin analogue) developed by Novo Nordisk — the first amylin receptor agonist designed for once-weekly dosing. Key research application: the CagriSema combination (cagrilintide + semaglutide) achieved 15.6% weight reduction at 32 weeks in Phase 2.
Every QSC cagrilintide batch: ≥99% HPLC purity, MS confirmed, Janoshik COA (verify at verify.janoshik.com). Shipping: International, 7-14 business days. Research use only.
Research Use Only. For in vitro laboratory research only. Not for human use.
